JP2020510404A - エンテロコッカス属細菌に対する新規抗微生物剤 - Google Patents
エンテロコッカス属細菌に対する新規抗微生物剤 Download PDFInfo
- Publication number
- JP2020510404A JP2020510404A JP2019518954A JP2019518954A JP2020510404A JP 2020510404 A JP2020510404 A JP 2020510404A JP 2019518954 A JP2019518954 A JP 2019518954A JP 2019518954 A JP2019518954 A JP 2019518954A JP 2020510404 A JP2020510404 A JP 2020510404A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- polypeptide
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000194033 Enterococcus Species 0.000 title claims abstract description 19
- 239000004599 antimicrobial Substances 0.000 title abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 214
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 156
- 229920001184 polypeptide Polymers 0.000 claims abstract description 139
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 127
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 54
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 42
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 42
- 239000013598 vector Substances 0.000 claims abstract description 28
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 24
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 22
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims abstract description 18
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims abstract description 18
- 125000002091 cationic group Chemical group 0.000 claims abstract description 17
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 17
- 108010002069 Defensins Proteins 0.000 claims abstract description 16
- 102000000541 Defensins Human genes 0.000 claims abstract description 16
- 101800002011 Amphipathic peptide Proteins 0.000 claims abstract description 12
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 42
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 39
- 241000894006 Bacteria Species 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 23
- 241000194032 Enterococcus faecalis Species 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 230000001747 exhibiting effect Effects 0.000 claims description 11
- 210000002421 cell wall Anatomy 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 241000194031 Enterococcus faecium Species 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 7
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 5
- 108010013639 Peptidoglycan Proteins 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 239000012620 biological material Substances 0.000 claims description 3
- 239000002639 bone cement Substances 0.000 claims description 3
- 238000011109 contamination Methods 0.000 claims description 3
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 32
- 125000000539 amino acid group Chemical group 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 31
- 238000006467 substitution reaction Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108010014251 Muramidase Proteins 0.000 description 7
- 102000016943 Muramidase Human genes 0.000 description 7
- 235000010335 lysozyme Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 230000009036 growth inhibition Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- -1 SH groups Chemical group 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 230000003641 microbiacidal effect Effects 0.000 description 3
- 229940051921 muramidase Drugs 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000013026 undiluted sample Substances 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 241000256837 Apidae Species 0.000 description 2
- 241000239223 Arachnida Species 0.000 description 2
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010022172 Chitinases Proteins 0.000 description 2
- 102000012286 Chitinases Human genes 0.000 description 2
- 101710184994 Complement control protein Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 2
- 102100030397 N-acetylmuramoyl-L-alanine amidase Human genes 0.000 description 2
- 241000270934 Rana catesbeiana Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 241001233037 catfish Species 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 108010060371 endo-N-acetylmuramidase Proteins 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VFERDGRYIBXYRG-REVLRCOSSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 VFERDGRYIBXYRG-REVLRCOSSA-N 0.000 description 1
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 206010060921 Abdominal abscess Diseases 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241001136816 Bombus <genus> Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241001415440 Bufo gargarizans Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241001053330 Enterobacteria phage C-1 Species 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 101000925646 Enterobacteria phage T4 Endolysin Proteins 0.000 description 1
- 206010014889 Enterococcal infections Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710168479 Granulysin Proteins 0.000 description 1
- 102100021186 Granulysin Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- 241000239205 Merostomata Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 1
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241001417871 Silurus asotus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000002353 algacidal effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 102000018568 alpha-Defensin Human genes 0.000 description 1
- 108050007802 alpha-defensin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003569 amebicidal effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011482 antibacterial activity assay Methods 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010069603 bacteriophage repressor protein C1 Proteins 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 102000018511 hepcidin Human genes 0.000 description 1
- 108060003558 hepcidin Proteins 0.000 description 1
- 229940066919 hepcidin Drugs 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229940030793 psoriasin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- WPUMTJGUQUYPIV-UHFFFAOYSA-L sodium malate Chemical compound [Na+].[Na+].[O-]C(=O)C(O)CC([O-])=O WPUMTJGUQUYPIV-UHFFFAOYSA-L 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/32—Organic compounds
- A61L2101/46—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
i)配列番号2で示されるアミノ酸配列、
ii)配列番号3で示されるアミノ酸配列、
iii)配列番号5で示されるアミノ酸配列、および、
iv)配列番号2、配列番号3、または配列番号5の何れか1つの誘導体であって、配列番号2、配列番号3、または配列番号5に対してそれぞれ少なくとも80%の配列同一性を呈する誘導体、
からなる群から選択される配列であり、また
前記第2アミノ酸配列は、抗微生物ペプチド,両親媒性ペプチド,カチオン性ペプチド,疎水性ペプチド,スシペプチドまたはデフェンシンであることを特徴とする。
以下の配列:
i)配列番号2で示されるアミノ酸配列、
ii)配列番号3で示されるアミノ酸配列、および
iii)配列番号5で示されるアミノ酸配列、
からなる群から選択される配列である。
配列番号1の特に有用な誘導体は、
配列番号5(配列番号1のN末端メチオニンが欠失している)およびこれらの誘導体に加えて、配列番号2もしくは配列番号3、またはこれらの誘導体が含まれる、配列番号1の切断配列を持つポリペプチドである。これらすべての実施形態に共通していることは、本発明のペプチドには、配列番号1のアミノ酸配列が含まれないことである。
LB(ルリア−ベルターニ)培地でエンテロコッカス・フェカーリス細菌を一晩培養し、同培地に10倍で希釈させた。約0.6の光学濃度OD600の細菌をペレット化し、緩衝液(10mMのHEPES,pH7.4)中で洗浄し、同緩衝液に10倍で希釈させた。50μlの細菌溶液を、50μlのタンパク質溶液(300mMのNaCl,20mMのHEPES中に10μg,pH7.4)または対照群(20mMのHEPES,300mMのNaCl,pH7.4)と混合させた。使用されたタンパク質は配列番号1で示される野生型エンドリシン(wt)および配列番号93を含む本発明に係るポリペプチドであった。各サンプルを60分間37℃で緩やかに攪拌しながら培養した。25μlの非希釈サンプルと1×PBS緩衝溶液中の10倍希釈系列をLB寒天プレート上にプレーティングし、これらを37℃で一晩培養した。コロニーを計数して増殖抑制を調べた。
LB(ルリア−ベルターニ)培地でエンテロコッカス・フェカーリス細菌を培養し、同培地に10倍で希釈させた。約0.6の光学濃度OD600の細菌をペレット化し、様々な緩衝液中で洗浄した。使用された緩衝液は以下の通りであった。100mMのリンゴ酸二ナトリウム塩、pH5およびpH6の緩衝液、ならびに1M Na2HPO4と1M NaH2PO4の混合物、pH7.4およびpH8の緩衝液。細菌をその後、異なる緩衝液(上を参照)に10倍で希釈させた。50μlの細菌溶液を、50μlのタンパク質溶液(20mMのHEPES,300mMのNaCl中に10μg,pH7.4)または対照群(20mMのHEPES,300mMのNaCl,pH7.4)と混合させた。使用されたタンパク質は配列番号1で示される野生型エンドリシン(wt)および配列番号93を含む本発明に係るポリペプチドであった。細菌とタンパク質を混合した後の最終pH値は以下の通りであった:pH5.25,pH6.5,pH7.4およびpH7.75。各サンプルを60分間37℃で緩やかに攪拌させながら培養した。25μlの非希釈サンプルと1×PBS緩衝溶液中の10倍希釈系列をLB寒天プレート上にプレーティングし、これらを37℃で一晩培養した。コロニーを計数して増殖抑制を調べた。4回の10倍希釈が行われ、5logの対数減少の試験計数限界に達した。
LB(ルリア−ベルターニ)培地で細菌を一晩培養し、同培地に10倍で希釈させた。約0.6の光学濃度OD600の細菌をペレット化し、緩衝液(10mMのHEPES,pH7.4)中で洗浄し、同緩衝液に10倍で希釈させた。50μlの細菌溶液を、50μlのタンパク質溶液(300mMのNaCl,20mMのHEPES中に10μg,pH7.4)または対照群(20mMのHEPES,300mMのNaCl,pH7.4)と混合させた。使用されたタンパク質は配列番号1で示される野生型エンドリシン(wt)および配列番号93を含む本発明に係るポリペプチドであった。各サンプルを60分間37℃で緩やかに攪拌しながら培養した。25μlの非希釈サンプルと1×PBS緩衝溶液中の10倍希釈系列をLB寒天プレート上にプレーティングし、これらを37℃で一晩培養した。コロニーを計数して増殖抑制を調べた。4回の10倍希釈が行われ、5logの対数減少の試験計数限界に達した。
Claims (22)
- 第1アミノ酸配列と第2アミノ酸配列を含み、
前記第1アミノ酸配列は、
i)配列番号2で示されるアミノ酸配列、
ii)配列番号3で示されるアミノ酸配列、
iii)配列番号5で示されるアミノ酸配列、および
iv)配列番号2、配列番号3、または配列番号5で示されるアミノ酸配列のうち何れか1つの誘導体であって、配列番号2、配列番号3、または配列番号5と、それぞれが少なくとも80%の配列同一性を呈する誘導体、
からなる群から選択される配列であって、
前記第2アミノ酸配列は、抗微生物ペプチド、両親媒性ペプチド、カチオン性ペプチド、疎水性ペプチド、スシペプチドまたはデフェンシンである、
ことを特徴とするポリペプチド。 - 前記第1アミノ酸配列が、
i)配列番号2で示されるアミノ酸配列、
ii)配列番号3で示されるアミノ酸配列、および
iii)配列番号5で示されるアミノ酸配列、
からなる群から選択されることを特徴とする請求項1に記載のポリペプチド。 - 前記ポリペプチドに配列番号3もしくはその誘導体で示される配列、およびさらなるアミノ酸配列が含まれ、前記さらなるアミノ酸配列は、細菌の細胞壁、特にグラム陽性菌の細胞壁を分解可能な酵素であることを特徴とする、請求項1または2に記載のポリペプチド。
- 前記酵素が配列番号104で示されるアミノ酸配列であるか、または配列番号104に対して少なくとも80%、少なくとも85%、少なくとも87.5%、少なくとも90%、少なくとも91%、少なくとも92%、少なくとも93%、少なくとも94%、少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、少なくとも99%、もしくは99%を超える配列同一性を呈している配列番号104の誘導体、であることを特徴とする請求項3に記載のポリペプチド。
- 前記ポリペプチドに配列番号2のアミノ酸配列と配列番号3のアミノ酸配列が含まれていることを特徴とする請求項1〜4のいずれか一項に記載のポリペプチド。
- 前記誘導体が配列番号2、配列番号3、または配列番号5のそれぞれに対して、少なくとも85%、少なくとも87、5%、少なくとも90%、少なくとも91%、少なくとも92%、少なくとも93%、少なくとも94%、少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、少なくとも99%、または99%を超える配列同一性を呈することを特徴とする請求項1または3に記載のポリペプチド。
- 前記第2アミノ酸配列が、
i)配列番号4、配列番号31〜83、および配列番号100からなる群から選択される抗微生物ペプチド、
ii)配列番号87、配列番号88および配列番号89からなる群から選択される両親媒性ペプチド、
iii)配列番号6〜30からなる群から選択されるカチオン性ペプチド、
iv)配列番号84で示されるスシペプチド、または、
v)配列番号85および配列番号86からなる群から選択される疎水性ペプチド、
であることを特徴とする請求項1〜6のいずれか一項に記載のポリペプチド。 - 前記第2アミノ酸配列が配列番号4または配列番号100で示されるアミノ酸配列であることを特徴とする請求項1〜7のいずれか一項に記載のポリペプチド。
- i)前記第1アミノ酸配列は配列番号5もしくはその誘導体であり、前記第2アミノ酸配列は配列番号4であり、特に前記ポリペプチドに配列番号93のアミノ酸配列もしくは、配列番号93と少なくとも80%の配列同一性を呈する配列番号93の誘導体が含まれるか、または、
ii)前記第1アミノ酸配列は配列番号5もしくはその誘導体であり、前記第2アミノ酸配列は配列番号100であり、特に前記ポリペプチドに配列番号103のアミノ酸配列もしくは、配列番号103と少なくとも80%の配列同一性を呈する配列番号103の誘導体が含まれるか、または、
iii)前記第1アミノ酸配列は配列番号3もしくはその誘導体であり、前記第2アミノ酸配列は配列番号100であり、特に前記ポリペプチドに追加で配列番号104のアミノ酸配列もしくは、配列番号104と少なくとも80%の配列同一性を呈する配列番号104の誘導体が含まれる、
ことを特徴とする請求項1〜8のいずれか一項に記載のポリペプチド。 - 前記ポリペプチドがエンテロコッカス属細菌のペプチドグリカン、特にエンテロコッカス・フェカーリス細菌、および/または、エンテロコッカス・フェシウム細菌のペプチドグリカンを分解することを特徴とする請求項1〜9のいずれか一項に記載のポリペプチド。
- 前記ポリペプチドは、pH7.4などの略生理的なpHで、
野生型酵素(配列番号1)と比較してより活性が高く、および/または、
略生理的なpHのときに、pH5.25あるいはpH6など、より酸性度の高い生理的pHのときと比較して、実質的に同程度かまたはより高い活性を呈することを特徴とする請求項10に記載のポリペプチド。 - 請求項1〜11のいずれか一項に記載のエンドリシンと、薬学的に許容される担体、希釈剤、または賦形剤と、が含まれることを特徴とする組成物。
- 前記組成物が骨セメントであるかまたは生体材料を含むことを特徴とする請求項12に記載の組成物。
- 人体もしくは動物体を手術もしくは治療により手当する方法、または人体もしくは動物体に施される診断方法で使用されることを特徴とする、請求項1〜11のいずれか一項に記載のポリペプチドまたは請求項12〜13のいずれか一項に記載の組成物。
- 前記ポリペプチドまたは前記組成物が、細菌感染症の防止または治療、特にエンテロコッカス・フェカーリス細菌、および/または、エンテロコッカス・フェシウム細菌による感染症の防止または治療に使用されることを特徴とする、請求項14に記載された使用のためのポリペプチドまたは組成物。
- 前記ポリペプチドまたは前記組成物が、略生理的なpH、例えば約7.2〜約7.6のpH、より好ましくは約7.4のpHで使用されることを特徴とする、請求項14または15に記載された使用のためのポリペプチドまたは組成物。
- 無生物の表面、組成物、および/または、物体を、特に院内環境または診療所で消毒するための、請求項1〜11のいずれか一項に記載のポリペプチドの使用、または請求項12に記載の組成物の使用。
- 無生物の表面、組成物、および/または、物体の細菌による汚染を防止するため、特にエンテロコッカス・フェカーリス細菌、および/または、エンテロコッカス・フェシウム細菌による汚染を防止するための、請求項1〜11のいずれか一項に記載のポリペプチドの使用、または請求項12に記載の組成物の使用。
- 前記ポリペプチドまたは前記組成物が、略生理的なpH、例えば約7.2〜7.6のpH、より好ましくは約7.4のpHで使用されることを特徴とする、請求項17または18に記載の使用。
- 請求項1〜11のいずれか一項に記載のポリペプチドをコードする核酸。
- 請求項20に記載の核酸を含むベクター。
- 請求項1〜11のいずれか一項に記載のポリペプチド、請求項20に記載の核酸、および/または、請求項21に記載のベクター、を含む宿主細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16194788.2 | 2016-10-20 | ||
EP16194788 | 2016-10-20 | ||
PCT/EP2017/076861 WO2018073416A1 (en) | 2016-10-20 | 2017-10-20 | New antimicrobial agents against enterococcus bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020510404A true JP2020510404A (ja) | 2020-04-09 |
JP7288851B2 JP7288851B2 (ja) | 2023-06-08 |
Family
ID=57184337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019518954A Active JP7288851B2 (ja) | 2016-10-20 | 2017-10-20 | エンテロコッカス属細菌に対する新規抗微生物剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190330608A1 (ja) |
EP (1) | EP3528837A1 (ja) |
JP (1) | JP7288851B2 (ja) |
KR (1) | KR102560651B1 (ja) |
CN (1) | CN110087675A (ja) |
AU (1) | AU2017345217B2 (ja) |
BR (1) | BR112019007979A2 (ja) |
CA (1) | CA3041190A1 (ja) |
EA (1) | EA201990856A1 (ja) |
MX (1) | MX2019004439A (ja) |
SG (1) | SG11201902876TA (ja) |
WO (1) | WO2018073416A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210014673A (ko) | 2018-05-30 | 2021-02-09 | 뤼산도 아게 | 신규 항균성 단백질 |
EP3771463A1 (en) * | 2019-07-29 | 2021-02-03 | Ludwig-Maximilians-Universität München | Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances |
CN110950947B (zh) * | 2019-12-19 | 2022-04-29 | 温州大学 | 一种南美树蛙宿主防御肽dms-ps2及其基因和应用 |
WO2022154287A1 (ko) * | 2021-01-15 | 2022-07-21 | 주식회사 인트론바이오테크놀로지 | 엔테로코쿠스 패슘 균에 대하여 용균활성을 갖는 항균단백질 efl200 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070025978A1 (en) * | 2005-06-30 | 2007-02-01 | Pauline Yoong | Bactiophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
JP2012530510A (ja) * | 2009-06-26 | 2012-12-06 | ライサンド アクツィエンゲゼルシャフト | 抗微生物剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8816693D0 (en) | 1988-07-13 | 1988-08-17 | Agricultural & Food Res | Viral enzyme & gene |
WO1991019512A1 (en) * | 1990-06-21 | 1991-12-26 | University Of Georgia Research Foundation, Inc. | Antimicrobial peptides |
WO2014052438A1 (en) * | 2012-09-25 | 2014-04-03 | Regents Of The University Of Minnesota | Methods for making and using antimicrobial peptides |
GB201302042D0 (en) * | 2013-02-05 | 2013-03-20 | Plant Bioscience Ltd | Novel polypeptides having endolysin activity and uses thereof |
-
2017
- 2017-10-20 JP JP2019518954A patent/JP7288851B2/ja active Active
- 2017-10-20 CA CA3041190A patent/CA3041190A1/en active Pending
- 2017-10-20 WO PCT/EP2017/076861 patent/WO2018073416A1/en unknown
- 2017-10-20 SG SG11201902876TA patent/SG11201902876TA/en unknown
- 2017-10-20 US US16/343,069 patent/US20190330608A1/en not_active Abandoned
- 2017-10-20 EA EA201990856A patent/EA201990856A1/ru unknown
- 2017-10-20 AU AU2017345217A patent/AU2017345217B2/en active Active
- 2017-10-20 KR KR1020197014385A patent/KR102560651B1/ko active IP Right Grant
- 2017-10-20 EP EP17794266.1A patent/EP3528837A1/en active Pending
- 2017-10-20 BR BR112019007979A patent/BR112019007979A2/pt unknown
- 2017-10-20 CN CN201780065349.5A patent/CN110087675A/zh active Pending
- 2017-10-20 MX MX2019004439A patent/MX2019004439A/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070025978A1 (en) * | 2005-06-30 | 2007-02-01 | Pauline Yoong | Bactiophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
JP2012530510A (ja) * | 2009-06-26 | 2012-12-06 | ライサンド アクツィエンゲゼルシャフト | 抗微生物剤 |
Also Published As
Publication number | Publication date |
---|---|
WO2018073416A1 (en) | 2018-04-26 |
AU2017345217B2 (en) | 2024-05-02 |
KR102560651B1 (ko) | 2023-07-26 |
BR112019007979A2 (pt) | 2019-07-09 |
SG11201902876TA (en) | 2019-05-30 |
CN110087675A (zh) | 2019-08-02 |
MX2019004439A (es) | 2019-09-26 |
KR20190067236A (ko) | 2019-06-14 |
CA3041190A1 (en) | 2018-04-26 |
AU2017345217A1 (en) | 2019-04-18 |
EP3528837A1 (en) | 2019-08-28 |
EA201990856A1 (ru) | 2019-10-31 |
JP7288851B2 (ja) | 2023-06-08 |
US20190330608A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2765810C (en) | Antimicrobial endolysin fusion proteins | |
EP3129044B1 (en) | Peptidoglycan hydrolase for use in the treatment of chronic bacterial infections | |
JP7112396B2 (ja) | 黄色ブドウ球菌に対する新規抗微生物剤 | |
KR20200012844A (ko) | 조작된 그람-음성 엔도리신 | |
JP7288851B2 (ja) | エンテロコッカス属細菌に対する新規抗微生物剤 | |
EP3105322B1 (en) | Antimicrobial agents | |
AU2017255962B2 (en) | Antimicrobial agents against Salmonella bacteria | |
US11958890B2 (en) | Antimicrobial proteins | |
JP2024059797A (ja) | 新規抗微生物融合タンパク質 | |
JP7515535B2 (ja) | 黄色ブドウ球菌に対する新規抗微生物剤 | |
JP7515409B2 (ja) | 新規抗微生物融合タンパク質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200924 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211203 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20220330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220722 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230509 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230529 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7288851 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |